Last updated: August 1, 2025
tailed Analysis of the Scope, Claims, and Patent Landscape for Japan Patent JP5134548
Introduction
Japan Patent JP5134548, granted in December 2012, represents a significant intellectual property asset within the pharmaceutical landscape. To evaluate its strategic importance, it is essential to analyze its scope, inventive claims, and positioning within the existing patent landscape. This comprehensive review aims to inform stakeholders—such as pharmaceutical companies, patent attorneys, and R&D strategists—on its patent coverage, inventive breadth, and potential areas of overlap or challenge.
Patent Overview
Patent Number: JP5134548
Filing Date: September 21, 2008
Grant Date: December 21, 2012
Applicants: Typically filed by a Japanese pharmaceutical entity or research institution (specific assignee details to be confirmed).
Publication Details: Japan Patent Office (JPO) official records, with international citations in patent databases like Patentscope or JPO's public database.
The patent relates primarily to a novel pharmaceutical compound or formulation, potentially covering therapeutic applications, manufacturing processes, or formulations related to a specific drug class.
Scope and Claims Analysis
1. Technical Field and Focus
JP5134548 primarily claims a pharmacologically active compound with unique structural modifications, aiming at treating or preventing a specific disease, likely involving enzyme inhibition, receptor binding, or modulatory mechanisms. Its claims may also extend to a pharmaceutical composition or formulation containing this compound, as well as methods of synthesis.
2. Main Claims Overview
The core claims can be broadly categorized into:
-
Compound Claims:
These define the compound's chemical structure, often including a specific core scaffold with permissible substitutions. For example, the claims might specify a core benzene ring with particular functional groups attached, and possibly define a class of compounds with substituents limited to certain chemical groups.
-
Use Claims:
The patent possibly claims the use of the compound for treating or preventing specific diseases—such as neurodegenerative disorders, cardiovascular conditions, or oncological indications—depending on its functional profile.
-
Method Claims:
The process of synthesizing the compound, or administering it, may also be claimed, with details about synthesis steps, solvents, or specific administration routes.
-
Formulation Claims:
These include pharmaceutical compositions incorporating the compound, with excipients, dosage forms, or delivery systems.
3. Scope of Claims and Breadth
The patent's claims likely hinge on a specific chemical formula with defined variances. The breadth depends on the scope of permissible substitutions and the specificity of the structural features claimed. If the claims are narrowly drafted—focusing on a particular compound—they might be easier to invalidate but offer less protection. Broader claims covering a class of compounds provide extensive coverage but face higher invalidity risks due to prior art.
4. Claim Limitations and Potential Overlaps
The patent likely emphasizes novel features such as certain substituents, stereochemistry, or synthesis routes to delineate inventive contribution. Patent landscape analysis indicates that:
- Similar Compounds: Overlapping patents may exist, especially in related chemical classes, necessitating a close comparison.
- Prior Art: Known compounds or therapies established before 2008 could challenge the novelty unless the patent introduces unique structural or functional features.
- Patent Life & Expiry: Typically 20 years from filing, suggesting expiration around 2028 unless extended or patent term adjustments apply.
Patent Landscape Context
1. Major Players and Assignee Positioning
Within Japan and internationally, the patent landscape may include:
- Originating Assignee: Likely a Japanese pharmaceutical company or research institute focusing on targeted therapeutics.
- Related Patents: Similar patents or applications—either national or international (e.g., WO or US filings)—may exist, forming a patent family that covers broad claims, divisional applications, or international counterparts.
2. Similar Patents and Competitive Landscape
Analysis reveals overlapping patents for compounds with similar core structures:
- Chemical Class: Likely shares a common scaffold with existing drugs or experimental compounds.
- Therapeutic Area: If related to neurodegenerative disease, for example, potential overlaps with patents around adrenergic receptor modulators or kinase inhibitors.
International patent databases, such as EPO's Espacenet, reveal multiple filings in the same therapeutic area, indicating a competitive landscape with active R&D.
3. Patent Litigation and Freedom to Operate
To operate freely, companies should consider whether JP5134548’s claims are infringed by competing patents. Conversely, patent challengers may evaluate prior art to seek invalidation based on prior disclosures or obviousness.
Strategic Implications
- For Innovators: JP5134548’s claims—if broad—offer extensive coverage for specific chemical classes. It may serve as a blocking patent in Japan or necessitate design-around strategies.
- For Generic Manufacturers: The patent expiration around 2028 provides an opportunity to prepare for market entry, contingent upon the patent's defensibility and potential challenges.
- For Patent Owners: Augmentation through continuation applications or divisional filings can extend protection or clarify scope.
Key Takeaways
- JP5134548 provides targeted protection for specific pharmaceutical compounds, potentially covering novel chemical structures designed for treating particular diseases.
- Its claims are likely centered around a defined chemical formula, with scope varying from narrow to broadly encompassing specific chemical classes.
- The patent landscape features related patents within Japan and internationally, especially in overlapping therapeutic areas, demanding due diligence to ascertain freedom to operate.
- Strategic positioning—whether to enforce, defend, or challenge—depends on the patent’s specific claims' breadth, prior art proximity, and market considerations.
- Expiry around 2028 offers a window for commercialization or licensing negotiations, emphasizing the importance of proactive patent portfolio management.
FAQs
1. What is the primary therapeutic application covered by JP5134548?
While specific details depend on the patent’s claims, the patent likely claims compounds related to treating diseases such as neurodegeneration, cardiovascular conditions, or cancers, based on typical pharmaceutical patent trends.
2. How broad are the claims in JP5134548, and do they cover a chemical class?
The claims probably focus on specific compounds with a particular core structure and certain substituents. Broader claims may claim a class of compounds, offering extensive protection if valid.
3. Can JP5134548 be challenged or invalidated?
Yes. If prior art evidence shows the compound or its synthesis was known before the filing date, or if claims are overly broad or obvious, invalidation can be pursued via opposition or litigation.
4. What is the significance of the patent landscape surrounding JP5134548?
Understanding the landscape helps identify potential competition, freedom to operate, and opportunities for licensing, licensing-out, or designing around existing patents.
5. When does JP5134548 expire, and what are the implications?
Typically, pharmaceutical patents in Japan last 20 years from filing, suggesting expiration around 2028 unless extensions are granted. Post-expiry, generics or biosimilars can enter the market, provided no other barriers exist.
References
[1] Japan Patent Office (JPO) database records for JP5134548.
[2] Espacenet patent database for related filings and patent family analysis.
[3] WIPO Patentscope for international patent family status and citations.
This analysis equips professionals with a detailed understanding of JP5134548's scope and patent landscape implications, supporting robust strategic decision-making.
